Physician profile
Beverly Williams
NPI 1942860382
$822.93
in general payments reported to CMS, 2019-2025
15 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $13.10 · 2024: $450 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $171.80 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $121.85 | 2024 | Arexvy |
| Phathom Pharmaceuticals, INC. | $115.98 | 2024 | Voquezna |
| Coopersurgical, INC. | $70.92 | 2023-2025 | Paragard T 380a, Sos, Paragard T 380a |
| Hologic Sales and Service, LLC | $64.25 | 2025 | Aptima, Thinprep 2000 Processor |
| Inspire Medical Systems, INC. | $56.52 | 2025 | Inspire |
| Exeltis, USA INC. | $45.01 | 2025 | Slynd |
| Pfizer INC. | $38.55 | 2024 | |
| Organon LLC | $34.31 | 2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $23.92 | 2024 | Rexulti |
| Novo Nordisk INC | $19.61 | 2025 | Wegovy |
| Lilly USA, LLC | $15.64 | 2024 | Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $15.53 | 2024 | Gardasil 9, Gardasil |
| Exact Sciences Corporation | $15.46 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $13.58 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.